Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 27 September 2005
Vol. 2005, Issue 303, p. pe47
[DOI: 10.1126/stke.3032005pe47]

PERSPECTIVES

Evaluation of Selective Prostaglandin E2 (PGE2) Receptor Agonists as Therapeutic Agents for the Treatment of Asthma

K. F. Chung*

National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.

Abstract: Prostaglandin E2 (PGE2) released in asthmatic airways has bronchodilator properties and inhibits allergen-induced bronchoconstriction and release of inflammatory mediators. Although considered as a potential treatment for asthma, PGE2 also has some proinflammatory properties. PGE2 acts through four different receptor subtypes (EP1, EP2, EP3, and EP4) that may explain some of PGE2’s diverse effects. In a mouse model of allergic inflammation in which the four receptors were individually deleted, only EP3–/– mice showed an enhancement of inflammation, whereas an EP3 agonist was inhibitory, with PGE2 being inactive. Thus, EP3 agonists may lead to a new approach for the treatment of asthma. However, other PGE2 receptor subtypes may also have beneficial effects, and a greater understanding of the signaling pathways of these receptor subtypes will help to clarify the role of these receptors in asthma.

*Corresponding author. E-mail: f.chung{at}imperial.ac.uk

Citation: K. F. Chung, Evaluation of Selective Prostaglandin E2 (PGE2) Receptor Agonists as Therapeutic Agents for the Treatment of Asthma. Sci. STKE 2005, pe47 (2005).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Application of 'omics technologies to biomarker discovery in inflammatory lung diseases.
C. E. Wheelock, V. M. Goss, D. Balgoma, B. Nicholas, J. Brandsma, P. J. Skipp, S. Snowden, D. Burg, A. D'Amico, I. Horvath, et al. (2013)
Eur. Respir. J. 42, 802-825
   Abstract »    Full Text »    PDF »
E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling.
M. Serra-Pages, A. Olivera, R. Torres, C. Picado, F. de Mora, and J. Rivera (2012)
J. Leukoc. Biol. 92, 1155-1165
   Abstract »    Full Text »    PDF »
Prostaglandin E2 Activates and Utilizes mTORC2 as a Central Signaling Locus for the Regulation of Mast Cell Chemotaxis and Mediator Release.
H. S. Kuehn, M.-Y. Jung, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan (2011)
J. Biol. Chem. 286, 391-402
   Abstract »    Full Text »    PDF »
Genome-wide expression profiling of T-cells in childhood wheeze.
A. Bosco and P. G. Holt (2008)
Eur. Respir. J. 32, 1138-1140
   Full Text »    PDF »
Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate airway repair.
B. G. Zani, K. Kojima, C. A. Vacanti, and E. R. Edelman (2008)
PNAS 105, 7046-7051
   Abstract »    Full Text »    PDF »
Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells.
H. Hammad, M. Kool, T. Soullie, S. Narumiya, F. Trottein, H. C. Hoogsteden, and B. N. Lambrecht (2007)
J. Exp. Med.
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882